Fri, Aug 22, 2014, 11:02 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

NewLink Genetics Corporation (NLNK) Message Board

target3 11 posts  |  Last Activity: Aug 18, 2014 11:44 AM Member since: Dec 12, 1997
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "The story of Sierra Leone's "hero doctor" does not have a happy ending.

    Even though Dr. Sheik Umar Khan was an experienced virus warrior, and hemorrhagic fevers were his specialty, he tested positive for Ebola on July 22 and died in seven terrible days"

    Google, "Dying Sierra Leone Dr. Sheik Umar Khan never told Ebola drug was available"

    How did this man get infected if he had so much experience with viruses?

  • WHO says the outbreak is "vastly underestimated". There are also estimates that it will take 6 months to contain the outbreak. Ebola has been popping up since 1976, this is the worst outbreak. Humans are becoming more and more geographically mobile. Ebola is not going completely away on it's own. I suspect this time officials will take definitive measures to try to eliminate the Ebola threat once and for all.

    One outcome, yes full of conjecture, is that through emergency measures NLNK's vaccine is proven and "approved". Millions are vaccinated or millions of doses stockpiled over the next 18 months to control the virus for good. The situation is very fluid and I am sure there are many other possible outcomes that don't swing in NLNK's favor. The market is discounting the odds as we speak. The situation has some favorable odds of working out in NLNK's favor in a material way.

    For sure the spotlight has just been focused on the BioProctection division and even if the current Ebola vaccine does not work in NLNK's favor additional value will be assigned to NLNK's equity due to BioProtection. The current situation has an element of hype, it also has an element enduring intrinsic value.

  • Google, "The Truth About Afresa Inhalable Insulin: A Chat with Al Mann" circa 2009. Nothing has changed. It's a good read.

  • AF only missed by about 5 miles. The main point and why Al invested $1 billlion is that current forms of RAA take too long to peak then stay on board way to long. Afreeza matches much closer to the glucose demands of human body around mealtime. RAAs are still very close to peak glucose control when the body needs some of the meal, Afreeza is about gone in 3 hours. AF is way off the mark.

  • If you are a long term investor then what big buyers or sellers, shorts, and volume of shares traded doesn't matter one bit. Stock up this, or down this amount, mindless posts. Look at miles and miles of worthless posts about shorts, volume, yadda, yadda over the years on this board. It has not helped one long term investor, may actually cause damage to focus on noise.

    Current forms of rapid acting insulin's take too long to peak and stay on board too long as compared to how the pancreas and glucose demand is required for the human body. Afreeza is better for meals than other form of insulin or anything on the horizon. This is the science and it is sound. Secondly, we have top shelf management. Because we have FDA approval and diabetes is one of the largest markets in the world. Time is now our friend. Nobody knows the size of this market and who will pay what to partner with MNKD. Nobody. What we do know is the science is sound and time is on our side now. Very good management, very good science and now time is our friend. It's been a long road to get here and over time investors in this stock will be rewarded.

  • Reply to

    Update from ADA 2014 Scientific Sessions

    by whosbadwhosmad Jun 14, 2014 12:58 PM
    target3 target3 Jun 14, 2014 3:25 PM Flag

    Novo SCALE trail is just a false hope of saving some sales once AFREEZA is approved. The patients were put on a diet and exercise program and the drug makes the nauseous and gives them diarrhea and they lost a little bit of weight all while taking these shots. Good grief! AFREEZA GOING TO MONKEY HAMMER NOVO.

  • target3 by target3 Jun 9, 2014 12:31 PM Flag

    EPZM has some neat stuff going in the inhibitor space but early stage. Market has EPZM market cap at $800m million, NLNK at $600m. Seems odd. HAP is the Rodney Dangerfield of therapies.

  • target3 target3 Jun 9, 2014 10:25 AM Flag

    If MNKD gets a bid from big pharma they have to entertain it, it's the law. They don't have to take it but Al has sold many many companies. If they math is right, he would sell. Whatever is logical.

  • Reply to

    fools....just foolish thinking going on here

    by j.stalk Jun 9, 2014 9:33 AM
    target3 target3 Jun 9, 2014 9:37 AM Flag

    j.stalk ; You don't think that Novo, Lilly, et al are watching this very close? There is massive market cap and salaries wrapped up in the diabetes market. For a drug company it's one of the best markets ever in the history of mankind. Not to mention KFC's going up 3 per day around the world.

  • target3 target3 Jun 9, 2014 9:23 AM Flag

    JNJ is my best bet. They are loaded with cash and this is essentially a consumer product. It's a $50 billion dollar market, probably the largest market in the world and possibly growing the fastest of any large market. If FDA approves and labeling is reasonable the sparks are going to fly. Lots of big pharma need to protect turf. That's what the adcom was all about. FDA sending a signal to big pharma that they couldn't stop it anymore.

  • target3 by target3 Jun 4, 2014 10:35 AM Flag

    Anybody heard from him? Can we get a "likely to disappoint" 2014 or 2015 version?

NLNK
25.06+1.22(+5.12%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT
Salesforce.com, Inc
NYSEFri, Aug 22, 2014 4:00 PM EDT